Search results
3 No-Brainer Stocks to Buy in June | The Motley Fool
The Motley Fool· 6 days agoYou're probably familiar with the old adage, "April showers bring May flowers." Here's why they picked AbbVie (ABBV 3.15%), AstraZeneca (AZN 1.63%), and...
EMA CHMP recommends AstraZeneca’s Tagrisso for lung cancer
Pharmaceutical Technology via Yahoo Finance· 4 days agoThe Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has...
Why CEO AstraZeneca believes the drugmaker can almost double revenue by 2030
CNBC· 3 days agoAstraZeneca CEO Pascal Soriot explained in a Tuesday interview with CNBC's Jim Cramer why the...
Summit Therapeutics, AstraZeneca And More From The Year’s Biggest Cancer Conference
Forbes· 2 days agoThe American Society of Clinical Oncology held its annual conference in Chicago this past week,...
Patient’s Dark Fantasy About Aetna Lands Him in Jail
The Daily Beast via Yahoo News· 4 days agoMany Americans loathe their health insurance providers.A majority say they have severe concerns about financial hardship due to medical bills—even with...
With new Enhertu data, an ADC could overtake chemo in breast cancer
BioPharma Dive via Yahoo Finance· 6 days agoStudy participants had already received one hormone therapy and a type of drug called a CDK 4/6...
AbbVie's (ABBV) Ovarian Cancer Therapy Meets Study Goal
Zacks· 23 hours agoData from a mid-stage study shows that treatment with AbbVie's (ABBV) Elahere achieves an objective response rate of almost 52% in certain heavily pre-treated patients with ovarian cancer.
Tempus Announces Expansion of Collaboration with AstraZeneca to Leverage Tempus Next to Support...
Morningstar· 7 days agoTempus, a leader in artificial intelligence and precision medicine, today announces an expansion of its collaboration with AstraZeneca, which leverages Tempus Next to arm ...
Astra's Enhertu breast cancer trial shows 'unprecedented' results
Reuters via AOL· 6 days ago(Reuters) -AstraZeneca and Daiichi Sankyo's Enhertu slows the progression of breast cancer by about...
Astrazeneca (AZN) Beats Stock Market Upswing: What Investors Need to Know
Zacks· 5 days agoFree Report) closed the most recent trading day at $78.99, moving +1.24% from the previous trading session. This move outpaced the S&P 500's daily gain of 0.11%. Coming into today, shares of ...